Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 2:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,664 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Therapeutic Vaccine Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Specimen Collection Study From Coronavirus Disease 2019 (COVID-19) Vaccinated Adults and Adolescents

NCT05252910
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Pharm-Olam, LLC
Industry
Eligibility
12 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
6
States / cities
Boston, Massachusetts • Omaha, Nebraska • Syracuse, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 1 Interventional

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

NCT01176474
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)

NCT00001020
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1IIIB, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1995
U.S. locations
3
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 2 Interventional

Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma

NCT00938223
View directory record Official record
Conditions
Melanoma
Interventions
4-peptide and 12-peptide melanoma vaccines
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Community Pharmacists Vaccinate Against Cancer

NCT04072159
View directory record Official record
Conditions
Human Papillomavirus Vaccines
Interventions
Community Pharmacists Vaccinating Against Cancer
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

NCT00111579
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T, TIV
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 36 Months
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
5
States / cities
Layton, Utah • Ogden, Utah • Pleasant Grove, Utah + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2008 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

NCT01827462
View directory record Official record
Conditions
Influenza
Interventions
Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

NCT00715910
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Nimenrix, Blood sampling
Biological · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 30 Years
Enrollment
818 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
10
States / cities
Daly City, California • Fairfield, California • Redwood City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2014 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 1 Interventional

Phase 1a Study to Evaluate Immunogenicity of ASV®

NCT03673020
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
ASV® AGEN2017 + QS-21 Stimulon® adjuvant
Biological
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

NCT00003362
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
QS21, gp100 antigen, incomplete Freund's adjuvant, sargramostim, tyrosinase peptide
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Sep 25, 2026, 2:34 AM EDT
Not listed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00104780
View directory record Official record
Conditions
Lung Cancer
Interventions
EP-2101, incomplete Freund's adjuvant
Biological
Lead sponsor
Epimmune
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
9
States / cities
Ocoee, Florida • Albany, New York • Durham, North Carolina + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 25, 2026, 2:34 AM EDT
Completed No phase listed Observational

Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro

NCT01472627
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Blood draws
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults

NCT03382405
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
mRNA-1647, mRNA-1443, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
4
States / cities
Hollywood, Florida • Meridian, Idaho • Peoria, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 2 Interventional

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

NCT00014573
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 7, 2013 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

NCT02743455
View directory record Official record
Conditions
Yellow Fever, Yellow Fever Immunisation
Interventions
ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 1 Interventional

Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma

NCT01792505
View directory record Official record
Conditions
Malignant Glioma
Interventions
Dendritic Cell Vaccine in combination with Imiquimod cream
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 25, 2026, 2:34 AM EDT
Terminated Phase 2 Interventional Results available

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

NCT02978222
View directory record Official record
Conditions
Platinum Sensitive Ovarian Cancer, Ovarian Cancer
Interventions
FRα peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF) Alone
Biological · Drug
Lead sponsor
Marker Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 1 Interventional

A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant

NCT00001439
View directory record Official record
Conditions
Melanoma
Interventions
gp100 human melanoma peptide
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine

NCT00873912
View directory record Official record
Conditions
Healthy
Interventions
Monovalent influenza virus vaccine, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

NCT00024466
View directory record Official record
Conditions
Multiple Myeloma
Interventions
GVAX, Autologous transplant
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 25, 2026, 2:34 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

NCT07287137
View directory record Official record
Conditions
COVID -19, COVID - 19, COVID 19, Influenza, Respiratory Virus, Respiratory Viruses, Respiratory Virus Infection, Respiratory Virus Infections
Interventions
Pfizer-BioNTech mRNA COVID-19 vaccine, Novavax recombinant protein vaccine
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 79 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

NCT02608502
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSV-F Vaccine, Phosphate Buffer Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
11,850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
60
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 1 Interventional

A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas

NCT01130077
View directory record Official record
Conditions
Newly Diagnosed Pediatric Pontine Glioma, Newly Diagnosed Pediatric High Grade Glioma, Recurrent Pediatric High Grade Glioma, Recurrent Pediatric Low Grade Glioma
Interventions
HLA-A2 restricted glioma antigen peptides vaccine, Poly-ICLC
Biological
Lead sponsor
James Felker
Other
Eligibility
12 Months to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 25, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid

NCT01701999
View directory record Official record
Conditions
Botulism
Interventions
rBV A/B
Biological
Lead sponsor
California Department of Public Health
Other
Eligibility
18 Years to 69 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
2
States / cities
Richmond, California • West Jefferson, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 25, 2026, 2:34 AM EDT